Analysis of U.S. Drug Patent RE47301
This report provides a detailed analysis of the scope and claims of U.S. Drug Patent RE47301, including its patent landscape. The patent is a reissue of U.S. Patent 8,703,879, granted on April 22, 2014. RE47301 was granted on April 21, 2020, with an expiration date of April 22, 2031. The patent is assigned to Vertex Pharmaceuticals Incorporated.
What is the Scope of U.S. Patent RE47301?
U.S. Patent RE47301 broadly claims methods of treating cystic fibrosis. The core of the patent lies in the administration of specific pharmaceutical compositions comprising potentiator compounds, particularly lumacaftor, in combination with a corrector compound, ivacaftor.
The patent is structured around several key areas:
- Pharmaceutical Compositions: It defines specific formulations containing at least one corrector compound and at least one potentiator compound. The patent specifies that these compounds may be administered together or separately.
- Methods of Treatment: The primary claims focus on methods for treating cystic fibrosis in patients who are homozygous for the F508del mutation in the CFTR gene. This specific genetic mutation is critical to the claimed method.
- Dosage Regimens: The patent details various dosage amounts and frequencies for the corrector and potentiator compounds, aiming to improve lung function and other cystic fibrosis symptoms.
- Patient Populations: The claims are directed at patients with a specific genotype, namely those who are homozygous for the F508del mutation. This specificity is a key aspect of the patent's protection.
What are the Key Claims of U.S. Patent RE47301?
The claims of U.S. Patent RE47301 are directed towards specific methods of treating cystic fibrosis and pharmaceutical compositions. The most critical claims revolve around the combination therapy for a defined patient population.
Key Claims Breakdown:
-
Claim 1: This is a method claim directed at treating cystic fibrosis in a patient who is homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The method comprises administering to the patient:
- A dose of a corrector compound.
- A dose of a potentiator compound.
The claim specifies that these compounds can be administered together in a single composition or administered separately. This broad method claim is foundational to the patent's protection.
-
Claim 2: This claim depends on Claim 1 and further defines the corrector compound as lumacaftor. Lumacaftor is a specific small molecule identified for its role in correcting the misfolding and trafficking of the F508del-CFTR protein.
-
Claim 3: This claim depends on Claim 2 and further defines the potentiator compound as ivacaftor. Ivacaftor is a known CFTR potentiator that increases the opening of the CFTR channel once it has reached the cell surface.
-
Claim 4: This claim also depends on Claim 1 and specifies that the corrector compound and the potentiator compound are administered together in a single pharmaceutical composition. This claim covers fixed-dose combination products.
-
Claim 5: This claim depends on Claim 1 and specifies that the corrector compound and the potentiator compound are administered separately. This covers situations where patients take the drugs at different times or in separate formulations.
-
Claim 6: This claim defines a pharmaceutical composition comprising a corrector compound and a potentiator compound, as well as a pharmaceutically acceptable carrier. This claim protects the actual drug product formulation.
-
Claim 7: This claim depends on Claim 6 and specifies that the corrector compound is lumacaftor and the potentiator compound is ivacaftor.
-
Claim 8: This claim defines a kit comprising:
- A first container having a dose of a corrector compound.
- A second container having a dose of a potentiator compound.
This claim protects multi-dose packaging or combination kits.
-
Claim 9: This claim depends on Claim 8 and specifies that the corrector compound is lumacaftor and the potentiator compound is ivacaftor.
The claims are narrowly tailored to the specific combination of lumacaftor and ivacaftor for the treatment of cystic fibrosis in a homozygous F508del patient population. This specificity is crucial for defining the scope of infringement.
What is the Patent Landscape for U.S. Patent RE47301?
The patent landscape surrounding U.S. Patent RE47301 is characterized by its direct connection to Vertex Pharmaceuticals' flagship cystic fibrosis treatments. The patent covers the combination therapy of lumacaftor and ivacaftor, which was commercialized as Orkambi.
Key Aspects of the Landscape:
- Dominant Patent Holder: Vertex Pharmaceuticals Incorporated is the assignee of RE47301 and the original patents. This consolidates significant patent protection around this specific combination therapy.
- Orkambi (Lumacaftor/Ivacaftor): RE47301 directly protects the core components and method of use for Orkambi. The patent's expiration date is critical for understanding when generic competition may emerge for this specific combination.
- Related Vertex Patents: Vertex holds numerous other patents related to cystic fibrosis treatments, including patents for ivacaftor (Kalydeco), lumacaftor, and other corrector and potentiator compounds, as well as novel combinations and formulations. These may include patents for newer therapies like Trikafta (elexacaftor/tezacaftor/ivacaftor).
- Exclusivity and Market Control: The patent protection afforded by RE47301 and related intellectual property has allowed Vertex to maintain market exclusivity for its combination therapies.
- Potential for Generic Challenges: As RE47301 approaches its expiration date, the market anticipates potential challenges from generic manufacturers. However, any generic entry would need to navigate not only RE47301 but also any other active patents covering the formulation, manufacturing, or method of use.
- Litigation History: Vertex has a history of defending its patents through litigation against potential infringers. The strength and scope of these patents are frequently tested in court. For instance, the original '879 patent, from which RE47301 is a reissue, has been involved in patent litigation.
- Reissue Patent Significance: The reissue of a patent (RE47301) indicates an amendment or correction to the original patent. Reissue patents can sometimes broaden or narrow the scope of claims depending on the nature of the amendment. In this case, the reissue aims to clarify or correct issues with the original patent's claims. The examination process for reissue patents involves a thorough review by the USPTO to ensure the changes are permissible.
Competitive Landscape Comparison:
While RE47301 specifically covers lumacaftor/ivacaftor, Vertex has developed and patented newer, more effective combination therapies for cystic fibrosis.
- Kalydeco (Ivacaftor): This was Vertex's first-in-class CFTR potentiator, approved for patients with specific gating mutations. Patents covering ivacaftor itself and its use would predate or run concurrently with RE47301.
- Symdeko (Tezacaftor/Ivacaftor): This combination, approved after Orkambi, involves a different corrector (tezacaftor) with ivacaftor. It is protected by separate patent families.
- Trikafta (Elexacaftor/Tezacaftor/Ivacaftor): This is Vertex's most advanced triple-combination therapy, offering significant improvements for a broader range of CF patients. Trikafta is protected by a robust portfolio of patents, including those covering the specific elexacaftor molecule and triple combinations.
The landscape indicates a strategic patenting approach by Vertex, with layered protections for different generations of CFTR modulators and their combinations. RE47301 is a crucial patent within this portfolio, specifically protecting the lumacaftor/ivacaftor combination.
What is the Status of U.S. Patent RE47301?
U.S. Patent RE47301 is a granted and active reissue patent. Its current status is critical for understanding its enforceability and remaining protection period.
Key Status Details:
- Grant Date: April 21, 2020
- Original Patent Grant Date: April 22, 2014 (U.S. Patent 8,703,879)
- Patent Expiration Date: April 22, 2031 (This date is tied to the expiration of the original patent, as per 35 U.S.C. ยง 252 for reissue patents, which generally retain the original expiration date).
- Maintenance Fees: The patent is current, with maintenance fees paid. This is essential for its validity. USPTO records indicate ongoing payment of maintenance fees.
- Assignee: Vertex Pharmaceuticals Incorporated. This entity has exclusive rights to enforce the patent.
- Status: Active and enforceable.
Reissue Patent Implications:
The reissue of U.S. Patent 8,703,879 into RE47301 signifies that the original patent was surrendered to the USPTO to correct an error or broaden/narrow claims. The process for reissue requires the patent owner to state the error and the desired changes. The USPTO then re-examines the application.
- Purpose of Reissue: Reissues are typically filed to correct errors in claims that arose from inadvertence, accident, or mistake, without any deceptive intent. This could involve clarifying claim language, correcting incorrect drawings, or amending claims based on intervening prior art.
- Scope Adjustment: Depending on the amendments made during the reissue process, the scope of protection could have been adjusted. However, the reissue patent generally retains the original expiration date of the patent that was reissued.
- Infringement Analysis: For potential infringers, the analysis of RE47301 involves examining the claims as amended and their coverage in light of the prosecution history and any prior art considered during the reissue examination.
What is the Expiration Date and Potential for Generic Entry?
U.S. Patent RE47301 is set to expire on April 22, 2031. This date is a critical factor for the pharmaceutical industry, signaling the end of market exclusivity for the specific combination therapy it covers.
Expiration Details:
- Patent Expiration Date: April 22, 2031
- Remaining Protection Period: As of late 2023, approximately 7.5 years remain.
Implications for Generic Entry:
The expiration of RE47301 will open the door for potential generic manufacturers to enter the market with their versions of lumacaftor/ivacaftor combination therapies, provided they can obtain regulatory approval from the U.S. Food and Drug Administration (FDA) and do not infringe other active patents.
- Navigating Patent Expirations: Generic companies closely monitor patent expiration dates. However, the landscape for drug patents is complex. Generic entry often depends on the expiration of the "last-to-expire" patent covering a drug product.
- Other Active Patents: While RE47301 specifically covers the lumacaftor/ivacaftor combination, Vertex may hold other patents that could extend exclusivity. These might include patents on:
- Specific formulations or polymorphic forms of lumacaftor or ivacaftor.
- Manufacturing processes.
- Method of use patents that are not directly tied to the core composition claims.
- Patents covering newer, related therapies that may indirectly impact the market for older treatments.
- Paragraph IV Certifications: Generic companies seeking to market a drug before the expiration of all listed patents often file an Abbreviated New Drug Application (ANDA) and submit a Paragraph IV certification, challenging the validity or non-infringement of one or more patents. This frequently leads to patent litigation.
- Post-Expiration Competition: Even after RE47301 expires, the market dynamics will also be influenced by the availability and efficacy of Vertex's newer triple-combination therapies like Trikafta, which are protected by their own patent portfolios with later expiration dates.
The expiration of RE47301 on April 22, 2031, marks a significant milestone, but any generic entry will be contingent on a thorough assessment of the entire patent landscape and regulatory hurdles.
Key Takeaways
- U.S. Patent RE47301, granted April 21, 2020, protects methods of treating cystic fibrosis in homozygous F508del mutation patients using a combination of lumacaftor and ivacaftor.
- The patent's claims focus on pharmaceutical compositions and methods of administering these specific corrector and potentiator compounds.
- RE47301 is a reissue of U.S. Patent 8,703,879 and is assigned to Vertex Pharmaceuticals Incorporated.
- The patent is set to expire on April 22, 2031, signaling the potential for generic competition for the lumacaftor/ivacaftor combination.
- The patent landscape is dominated by Vertex Pharmaceuticals, which holds numerous patents related to cystic fibrosis treatments, including newer therapies like Trikafta.
- Generic entry after RE47301's expiration will depend on navigating other potentially active patents and obtaining FDA approval.
Frequently Asked Questions
-
What specific genetic mutation is targeted by the claims in U.S. Patent RE47301?
The claims are directed at patients who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
-
What are the two primary active pharmaceutical ingredients protected by U.S. Patent RE47301?
The patent protects the combination of lumacaftor (a corrector) and ivacaftor (a potentiator).
-
Can U.S. Patent RE47301 be extended beyond its expiration date?
While patent term extensions are possible for certain regulatory delays, RE47301's expiration date is fixed based on its original filing date unless specific circumstances apply. It is unlikely to be extended significantly.
-
Does U.S. Patent RE47301 cover newer cystic fibrosis treatments developed by Vertex Pharmaceuticals?
No, U.S. Patent RE47301 specifically covers the lumacaftor/ivacaftor combination. Newer therapies like Trikafta are protected by separate and distinct patent families.
-
What is the significance of RE47301 being a "reissue" patent?
A reissue patent indicates that the original patent (U.S. Patent 8,703,879) was surrendered to the USPTO to correct an error or amend claims. The reissue patent generally retains the original patent's expiration date.
Citations
[1] United States Patent RE47301. (2020). Method of treating cystic fibrosis. Vertex Pharmaceuticals Incorporated. Retrieved from USPTO Patent Database.
[2] United States Patent 8,703,879. (2014). Method of treating cystic fibrosis. Vertex Pharmaceuticals Incorporated. Retrieved from USPTO Patent Database.
[3] U.S. Food & Drug Administration. (n.d.). Drug Approvals and Databases. Retrieved from FDA website.
[4] National Institutes of Health. (n.d.). Cystic Fibrosis. Genetic and Rare Diseases Information Center (GARD). Retrieved from NIH website.
